HC Wainwright Predicts Absci’s Q1 Earnings (NASDAQ:ABSI)

Absci Co. (NASDAQ:ABSI) – HC Wainwright cut their Q1 2025 earnings per share (EPS) estimates for shares of Absci in a report issued on Wednesday, March 19th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings of ($0.27) per share for the quarter, down from their prior estimate of ($0.19). HC Wainwright currently has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Absci’s current full-year earnings is ($0.89) per share. HC Wainwright also issued estimates for Absci’s Q2 2025 earnings at ($0.28) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.83) EPS, FY2026 earnings at ($0.52) EPS, FY2027 earnings at ($0.31) EPS, FY2028 earnings at $0.20 EPS and FY2029 earnings at ($0.02) EPS.

A number of other equities research analysts have also weighed in on ABSI. KeyCorp lowered their target price on shares of Absci from $6.00 to $5.00 and set an “overweight” rating on the stock in a report on Wednesday, January 8th. Guggenheim reiterated a “buy” rating and issued a $10.00 price objective on shares of Absci in a research note on Thursday. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $9.00 target price on shares of Absci in a research note on Wednesday. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Absci has a consensus rating of “Buy” and a consensus target price of $8.57.

Absci Price Performance

Shares of NASDAQ ABSI opened at $3.01 on Friday. The firm’s 50-day moving average price is $3.86 and its 200-day moving average price is $3.66. The firm has a market capitalization of $383.28 million, a P/E ratio of -3.24 and a beta of 2.09. The company has a current ratio of 5.63, a quick ratio of 5.63 and a debt-to-equity ratio of 0.01. Absci has a 1-year low of $2.45 and a 1-year high of $6.72.

Absci (NASDAQ:ABSI) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.03). The business had revenue of $0.67 million during the quarter, compared to analyst estimates of $1.77 million. Absci had a negative net margin of 2,321.56% and a negative return on equity of 46.56%.

Institutional Investors Weigh In On Absci

A number of institutional investors and hedge funds have recently made changes to their positions in ABSI. FMR LLC raised its position in shares of Absci by 1.2% during the 3rd quarter. FMR LLC now owns 12,727,760 shares of the company’s stock valued at $48,620,000 after buying an additional 147,156 shares in the last quarter. ARK Investment Management LLC lifted its position in Absci by 30.4% in the fourth quarter. ARK Investment Management LLC now owns 8,265,936 shares of the company’s stock valued at $21,657,000 after purchasing an additional 1,928,314 shares during the last quarter. Fred Alger Management LLC boosted its position in Absci by 4.3% during the 3rd quarter. Fred Alger Management LLC now owns 7,566,618 shares of the company’s stock valued at $28,904,000 after buying an additional 309,843 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Absci by 0.8% during the fourth quarter. Geode Capital Management LLC now owns 1,949,810 shares of the company’s stock worth $5,110,000 after purchasing an additional 16,217 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. grew its position in shares of Absci by 28.5% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,143,829 shares of the company’s stock worth $2,997,000 after buying an additional 253,985 shares during the last quarter. Hedge funds and other institutional investors own 52.05% of the company’s stock.

About Absci

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit.